Denali Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Denali Therapeutics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-29.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 63% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / -22%In 3 years sales changed by -100% while total assets changed by -22%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-43.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 70% of Healthcare companies in United States.
Cash Cushion Ratio
+28%Cash, after subtracting all debt, equals 28% of its market value (net cash).
Higher than 67% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Denali Therapeutics Inc. made a loss over the last year. Denali Therapeutics Inc. owes $0.28 for every $1 it owns. Denali Therapeutics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossDenali Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.57The share price is 3.57 times Denali Therapeutics Inc.'s book value per share, higher than 61% of Healthcare companies in United States.
Market cap
$3.0 BThe total market value of all of Denali Therapeutics Inc.'s shares at today's price (share price × number of shares), larger than 80% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$835 MWhat Denali Therapeutics Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$5.22Net worth divided by the number of shares. The share price of $18.66 is 3.6 times this, which is the P/B above.
Return on equity (ROE)
-54.9%Denali Therapeutics Inc. lost 54.9% of its shareholders' money over the last year, lower than 54% of Healthcare companies in United States.
Owes vs Owns
0.28×Denali Therapeutics Inc. owes $0.28 for every $1 it owns (low), lower than 63% of Healthcare companies in United States.
Dividend yield
NoneDenali Therapeutics Inc. does not currently pay a dividend.
Profit growth
LossDenali Therapeutics Inc. made a loss in each of the last two years.
Cash vs debt
Net cashDenali Therapeutics Inc. held $831 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Denali Therapeutics Inc.: $3.0 B ÷ $835 M (30 Jun 2026) = 3.6.
What is Denali Therapeutics Inc.'s return on equity?
Denali Therapeutics Inc. lost 54.9% of its shareholders' money over the last year, lower than 54% of Healthcare companies in United States.
How much does Denali Therapeutics Inc. owe compared with what it owns?
Denali Therapeutics Inc. owes $0.28 for every $1 it owns (low), lower than 63% of Healthcare companies in United States.
Does Denali Therapeutics Inc. pay a dividend?
No. Denali Therapeutics Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.